Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for SUVN-G3031

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug SUVN-G3031?

SUVN-G3031 is an investigational drug.

There have been 7 clinical trials for SUVN-G3031. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2015.

The most common disease conditions in clinical trials are Cognition Disorders, Depressive Disorder, Major, and Depressive Disorder. The leading clinical trial sponsors are Suven Life Sciences Limited and [disabled in preview].

There are two US patents protecting this investigational drug and fifty-six international patents.

Recent Clinical Trials for SUVN-G3031
A Study to Evaluate Safety, and Efficacy of SUVN-G3031 in Patients With Narcolepsy With and Without CataplexySuven Life Sciences LimitedPhase 2
Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy SubjectsSuven Life Sciences LimitedPhase 1
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy SubjectsSuven Life Sciences LimitedPhase 1

See all SUVN-G3031 clinical trials

Clinical Trial Summary for SUVN-G3031

Top disease conditions for SUVN-G3031
Top clinical trial sponsors for SUVN-G3031

See all SUVN-G3031 clinical trials

US Patents for SUVN-G3031

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SUVN-G3031   Start Trial Compounds as histamine H3 receptor ligands Suven Life Sciences Limited (Hyderabad, IN)   Start Trial
SUVN-G3031   Start Trial Process for large scale production of N-[4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-2-(morpholin-4-yl) acetamide dihydrochloride Suven Life Sciences Limited (Hyderabad, IN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for SUVN-G3031

Drugname Country Document Number Estimated Expiration Related US Patent
SUVN-G3031 African Regional IP Organization (ARIPO) 3340 1989-12-31   Start Trial
SUVN-G3031 Australia 2011360550 1989-12-31   Start Trial
SUVN-G3031 Brazil 112013021496 1989-12-31   Start Trial
SUVN-G3031 Canada 2827567 1989-12-31   Start Trial
SUVN-G3031 China 103443093 1989-12-31   Start Trial
SUVN-G3031 Cyprus 1116721 1989-12-31   Start Trial
SUVN-G3031 Denmark 2694492 1989-12-31   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.